Literature DB >> 10863061

A study of postoperative radiotherapy in patients with non-small-cell lung cancer: a randomized trial.

Q F Feng1, M Wang, L J Wang, Z Y Yang, Y G Zhang, D W Zhang, W B Yin.   

Abstract

PURPOSE: To study the value of postoperative radiotherapy for non-small-cell lung cancer (NSCLC) with positive regional lymph metastases (NI or N2) after radical surgery.
MATERIALS AND METHODS: From February 1982 to October 1995, 366 patients with NSCLC and N1 or N2 disease were randomized into postoperative radiotherapy (S + R) (183 patients) and no further treatment (S alone) (182 patients). Postoperative radiotherapy (RT) was administrated 3-4 weeks after radical operation. Irradiated fields covered the bronchial stump, ipsilateral hilum, and most of the mediastinum. The midplane dose was 6000 cGy/30 fractions/6 weeks, with the spinal cord limited to 4000 cGy/20 fractions/4 weeks or less. One hundred thirty-four patients in S + R group and 162 patients in S alone group were evaluated. Clinical data were comparable in both arms, except for the numbers of N2 patients.
RESULTS: The 3-year and 5-year overall survival rates were 51.9% and 42.9% in the S + R group and 50.2% and 40.5% in the S alone Group (p = 0.56). The 3-year and 5-year disease-free survival rates were 50.7% +/- 4.7% and 42.9% +/- 5.2% in the S + R group vs. 44.4% +/- 4.3% and 38.2% +/- 4.5% in the S alone group (p = 0.28), respectively. In the patients with NI or T3-4 tumors, there was a trend toward improved survival in the S + R group, especially in the patients with T3-4N1M0. These patients demonstrated 20% improvement in overall survival (p = 0.092) and greater than 20% better disease-free survival (p = 0.057). Postoperative RT reduced local recurrence but had no impact on distant metastases.
CONCLUSION: Postoperative RT significantly reduced local relapses, but did not improve overall survival, due to a high frequency of distant metastases in this patient group.

Entities:  

Mesh:

Year:  2000        PMID: 10863061     DOI: 10.1016/s0360-3016(00)00509-5

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  33 in total

1.  Postoperative radiotherapy option based on mediastinal lymph node reclassification for patients with pN2 non-small-cell lung cancer.

Authors:  J Jin; Y Xu; X Hu; M Chen; M Fang; Q Hang; M Chen
Journal:  Curr Oncol       Date:  2020-06-01       Impact factor: 3.677

2.  The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy.

Authors:  Arya Amini; Arlene M Correa; Ritsuko Komaki; Joe Y Chang; Anne S Tsao; Jack A Roth; Stephen G Swisher; David C Rice; Ara A Vaporciyan; Steven H Lin
Journal:  Ann Thorac Surg       Date:  2012-07-21       Impact factor: 4.330

Review 3.  Advances in adjuvant systemic therapy for non-small-cell lung cancer.

Authors:  David Leong; Rajat Rai; Brandon Nguyen; Andrew Lee; Desmond Yip
Journal:  World J Clin Oncol       Date:  2014-10-10

4.  Postoperative radiotherapy for resected pathological stage IIIA-N2 non-small cell lung cancer: a retrospective study of 221 cases from a single institution.

Authors:  Honghai Dai; Zhouguang Hui; Wei Ji; Jun Liang; Jima Lu; Guangfei Ou; Zongmei Zhou; Qinfu Feng; Zefen Xiao; Dongfu Chen; Hongxing Zhang; Weibo Yin; Jie He; Luhua Wang
Journal:  Oncologist       Date:  2011-04-11

5.  Optimal sequencing of postoperative radiotherapy and chemotherapy in IIIA-N2 non-small cell lung cancer.

Authors:  Ugur Selek; Joe Y Chang
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

6.  Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with stage I/II non-small cell lung cancer: results from Cancer and Leukemia Group B 159902.

Authors:  Alice M Boylan; Xiaofei F Wang; Richard Ko; Patricia M Watson; Lin Gu; David Harpole; Raphael Bueno; Rosemary Kelly; Leslie Kohman; Robert Kratzke
Journal:  J Thorac Cardiovasc Surg       Date:  2012-09-29       Impact factor: 5.209

Review 7.  Evidence-based recommendations of postoperative radiotherapy in lung cancer from Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).

Authors:  A Gómez; J A González; F Couñago; C Vallejo; F Casas; N Rodríguez de Dios
Journal:  Clin Transl Oncol       Date:  2015-08-18       Impact factor: 3.405

Review 8.  Post-operative radiation therapy (PORT) in completely resected non-small-cell lung cancer.

Authors:  Yelena Krupitskaya; Billy W Loo
Journal:  Curr Treat Options Oncol       Date:  2009-04-22

9.  Patterns of care in hilar node-positive (N1) non-small cell lung cancer: A missed treatment opportunity?

Authors:  Matthew J Bott; Aalok P Patel; Vivek Verma; Traves D Crabtree; Daniel Morgensztern; Clifford G Robinson; Graham A Colditz; Saiama Waqar; Daniel Kreisel; A Sasha Krupnick; G Alexander Patterson; Stephen Broderick; Bryan F Meyers; Varun Puri
Journal:  J Thorac Cardiovasc Surg       Date:  2016-03-12       Impact factor: 5.209

10.  Risk factors for local and regional recurrence in patients with resected N0-N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy.

Authors:  J L Lopez Guerra; D R Gomez; S H Lin; L B Levy; Y Zhuang; R Komaki; J Jaen; A A Vaporciyan; S G Swisher; J D Cox; Z Liao; D C Rice
Journal:  Ann Oncol       Date:  2012-09-20       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.